Aortic & peripheral vascular disease
Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial
Primary resultResult — go to the resultHazard ratio 0.84 95% CI 0.68–1.05Authors' conclusion
Although no statistically significant benefit was observed on the primary intention-to-treat analysis, the findings provide new evidence supporting the rationale for anti-inflammatory therapy in further randomised trials.
Study context
- Population
- Hospital-based patients with non-severe, non-cardioembolic ischaemic stroke or high-risk TIA3,144 in ITT analysis
- Participants
- 3,154 patients
- Comparison
- Long-term colchicine plus usual care vs usual care only
- Colchicine and usual caren = 1,569
- Usual care alonen = 1,575reference
- Primary endpoint
- Composite of:
- First fatal or non-fatal recurrent ischaemic stroke
- MI
- Cardiac arrest
- Hospitalisation for unstable angina
Methodological detailsparallel-group, open-label, blinded endpoint assessment, two prespecified interim analyses, Ended early due to budget constraints attributable to the COVID-19 pandemic
- Parallel-group
- Open-label
- Blinded endpoint assessment
- Two prespecified interim analyses
- Ended early due to budget constraints attributable to the COVID-19 pandemic
Primary result
As reported in the abstract
Hazard ratio
0.84
95% CI 0.68–1.05
P = 0.12
Events by treatment group
Colchicine and usual carevs Usual care alone
HR 0.84 (95% CI 0.68–1.05); P = 0.12
Further findings
C-reactive protein · 28 days and 1, 2 and 3 years
- Lower C-reactive protein (CRP) with colchicine at all timepoints (no difference at baseline)
- P < 0.05
Safety
Serious adverse events
- Rates similar in both groups
Original publication
Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial. Lancet. Published 7 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →